Volume Alert - AGN 212.46 Allergan Inc $AGN Hit a high

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - AGN 212.46 Allergan Inc $AGN Hit a high today of 213.60 Closing the day 10:30 at 212.46 +3.26 +1.56% With a day low of 207.18 and a total volume of 2,902,723.

AGN Recent Posts: http://investorshangout.com/Allergan-AGN-50031/

AGN Allergan Inc Recent Headline News

Stock Market Today: S&P 500 Flexes Muscles After Global Markets Pop
at The Street - 2 mins ago
The S&P 500 shows some muscle on Tuesday, rocketing to a new record high as global markets rally.
URBN: 28.08 (-2.75), AGN: 212.00 (+2.80), HD: 96.05 (-1.98), ACT: 261.86 (+13.92), TERP: 33.66 (+7.82), TJX: 60.06 (-1.48), MDT: 71.87 (+2.68), GILD: 101.85 (+1.41), SUNE: 20.56 (+3.95), HIMX: 6.54 (-0.36), AAPL: 114.55 (+0.56), NOK: 7.98 (+0.31)

Jim Cramer: Which Stocks Stand Out as Winners? Here's My List
at The Street - 6 mins ago
There's a powerful collection of 'what's working.'
HON: 96.83 (+0.30), JAH: 66.82 (+0.13), CAH: 80.83 (+0.47), WMT: 83.73 (+0.16), PDCO: 46.64 (+0.38), EAT: 54.07 (+0.11), UPS: 106.53 (+0.06), JACK: 70.90 (+0.61), DLTR: 61.75 (+0.28), TGT: 66.73 (-0.40), COST: 139.00 (+0.53), AAL: 44.60 (+0.91), DG: 65.39 (+0.09), LOW: 58.18 (-0.71), MSFT: 49.05 (-0.41), HSIC: 131.98 (+1.04), BCR: 166.78 (+1.97), MCK: 205.18 (+0.80), IP: 54.92 (+0.08), EW: 127.31 (+1.08), FDO: 78.86 (unch), AZO: 567.52 (-0.54), MCD: 96.29 (+0.32), SHW: 240.50 (+1.19), XRAY: 53.10 (+0.49), AN: 57.47 (+0.13), F: 15.38 (-0.16), ACT: 261.86 (+13.92), BDX: 130.52 (+0.98), VRX: 141.47 (+4.74), MDT: 71.87 (+2.68), SNA: 136.04 (+1.15), GMCR: 157.75 (+3.25), AGN: 212.00 (+2.80), KMX: 55.15 (+0.49), YHOO: 51.83 (-0.54), WHR: 177.36 (+1.81), CMG: 659.71 (+1.39), AAPL: 114.55 (+0.56), AMZN: 327.03 (+3.98), HD: 96.05 (-1.98), ORLY: 177.75 (+0.45), FRGI: 56.52 (+0.86), ABC: 89.20 (+0.19), TJX: 60.06 (-1.48), GM: 32.16 (-0.15), JWN: 72.94 (-0.33), ROST: 80.59 (-0.75)

AGN INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Allergan Inc. in Connection With the Fairness of the Sale of the Company to Actavis plc -- AGN
PR Newswire - 35 mins ago
Levi & Korsinsky is investigating the Board of Directors of Allergan Inc. ("Allergan" or "the Company" (NYSE: AGN) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Actavis plc.
AGN: 212.00 (+2.80)

Stock Market News for November 18, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 1 hr 43 mins ago
Markets ended its choppy run yesterday on a mixed note after Japan unexpectedly slipped into a recession
AGN: 212.00 (+2.80), ACT: 261.84 (+13.90), EOG: 97.23 (+0.88), HAL: 49.35 (+0.12), HP: 77.46 (-0.79), MRO: 31.89 (+0.07), BHI: 65.38 (+0.15)

Zacks Investment Ideas feature highlights: Allergan, Actavis, Sketchers and Zeltiq Aesthetics
PR Newswire - 2 hrs 23 mins ago
Today, Zacks Investment Ideas feature highlights Features: Allergan (NYSE:AGN-Free Report), Actavis (NYSE:ACT-Free Report), Sketchers (NYSE:SKX-Free Report) and Zeltiq Aesthetics (Nasdaq:ZLTQ-Free Report).
AGN: 212.00 (+2.80)

Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - Tue Nov 18, 7:32AM CST

AGN: 212.00 (+2.80), VRX: 141.47 (+4.74), ACT: 261.84 (+13.90)

Downgrade Alert for Allergan (AGN)
Comtex SmarTrend(R) - Tue Nov 18, 6:55AM CST
Allergan (AMEX:AGN) was downgraded from Buy to Neutral at Guggenheim today. The stock closed yesterday at $209.20 on volume of 19.1 million shares, above average daily volume of 2.7 million. In the past 52 weeks, Allergan share prices have been bracketed by a low of $94.98 and a high of $213.91 and closed yesterday at $209.20, 120% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.8% while the 50-day MA has advanced 1.2%.
AGN: 212.00 (+2.80)

Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 42.97 (+1.06), BIIB: 304.65 (+2.23), GE: 26.91 (+0.30), NKE: 96.10 (+0.04), HAL: 49.33 (+0.10), TSN: 42.58 (-0.45), GSAT: 2.53 (-0.27), LULU: 44.96 (+0.54), AGN: 212.00 (+2.80), MACK: 8.84 (+0.22), WHR: 177.36 (+1.81), UA: 68.69 (-0.20), DSX: 7.84 (+0.02), ALNY: 90.38 (+1.40), MPC: 93.69 (+1.18), JCP: 7.35 (+0.09), SHW: 240.50 (+1.19), MBLY: 47.42 (+0.44), REGN: 409.72 (+10.07), BHI: 65.40 (+0.17)

Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 212.00 (+2.80), ACT: 261.83 (+13.89), VRX: 141.47 (+4.74), V: 249.63 (-0.17), ALXN: 190.80 (+4.02), CTSH: 52.85 (-0.21), MA: 83.64 (+0.44), ADS: 281.21 (+0.33)

Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 212.00 (+2.80), MRK: 60.05 (+0.59), ABBV: 65.82 (+0.78), BMY: 58.70 (+0.27)

Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 212.00 (+2.80), ACT: 261.83 (+13.89), AMAG: 36.25 (+1.49), BMY: 58.70 (+0.27)

NYSE stocks posting largest volume increases
AP - Mon Nov 17, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
AGN: 212.00 (+2.80), HAL: 49.34 (+0.11), BLT: 16.64 (+0.47), DKL: 40.28 (+0.28), BHI: 65.40 (+0.17)

Watch for Allergan to Potentially Pullback After Gaining 5.21% Yesterday
Comtex SmarTrend(R) - Mon Nov 17, 4:28PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $207.44 to a high of $213.91. Yesterday, the shares gained 5.2%, which took the trading range above the 3-day high of $200.60 on volume of 18.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN: 212.00 (+2.80)


Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 212.00 (+2.80), ACT: 261.83 (+13.89), VRX: 141.47 (+4.74), MRK: 60.05 (+0.59), VRX.TO: 160.05 (+5.65)

Halliburton and Allergan are big market movers
AP - Mon Nov 17, 3:33PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
EXH: 36.99 (+0.18), AGN: 212.00 (+2.80), HAS: 56.00 (-0.37), HAL: 49.35 (+0.12), DNR: 9.88 (-0.13), MITL: 10.21 (+0.01), FOLD: 6.27 (-0.43), BHI: 65.40 (+0.17)

Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 212.00 (+2.80), VRX: 141.47 (+4.74), ACT: 261.83 (+13.89), SAFM: 86.21 (+1.28), PPC: 31.49 (+0.55), MIK: 22.04 (+0.39), TSN: 42.58 (-0.45)

Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 327.03 (+3.98), HAS: 56.00 (-0.37), ACT: 261.83 (+13.89), VRX: 141.47 (+4.74), JIVE: 6.43 (+0.06), FB: 74.09 (-0.15), HAL: 49.33 (+0.10), DWA: 22.21 (-0.10), AGN: 212.00 (+2.80), LNKD: 223.92 (+0.64), BHI: 65.40 (+0.17), CRM: 62.83 (+0.32)

Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 212.00 (+2.80), VRX: 141.47 (+4.74), ACT: 261.83 (+13.89), LNKD: 223.92 (+0.64), FB: 74.09 (-0.15), HAL: 49.33 (+0.10), BHI: 65.40 (+0.17), Z: 116.30 (-1.56)

Most active New York Stock Exchange-traded stocks
AP - Mon Nov 17, 1:22PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
AGN: 212.00 (+2.80), GE: 26.91 (+0.30), F: 15.39 (-0.15), PFE: 30.64 (+0.32), HAL: 49.33 (+0.10), BAC: 17.17 (+0.08), DNR: 9.88 (-0.13), TWTR: 40.29 (-0.18), BHI: 65.40 (+0.17)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Baccarat's Luxe Campaign Courts the High-End Traveler

Updated Category News Views 5

Shining the Spotlight on a Crystal-Clear Vision When Baccarat decides to cast its net over the high-end travel market, they're not doing it with subtlety. Nope, they're going all out, and why wouldn't they? When you've got a brand that's synonymous with luxury, you have to play the part. Enter Adriana Lima, the supermodel who could probably sell sand in the Maldives if...

Continue Reading
dMY IV Settlement: Investor Rights and Key Dates

Updated Category News Views 4

dMY IV Settlement: What You Need to Know Listen up, folks! If you've got a stake in dMY Technology Group, Inc. IV, there's big news brewing. We're talking class action, settlement talks, and a cool $11 million on the line. Let's crack open what this means for you as a holder of dMY IV Class A common stock during December 2021's whirlwind. Who Can Get a Piece of the...

Continue Reading
Electrolux Trends: Q3 '26 Shows Resilience Amid Challenges

Updated Category News Views 4

Electrolux's Strategic Moves In A Tough Market Electrolux's Q3 2026 paints a gritty picture—yet there's a pulse of resilience underneath the numbers. Net sales bumped up to SEK 33,919m due to a 3.5% organic growth, showing the company's ability to swim through choppy waters. But let's not brush aside the sharp rocks they’re dodging: soaring raw materials and logistics...

Continue Reading
Sunlife's Q3 2026 Results: Market Awaits Key Insights

Updated Category News Views 5

Sunlife Prepares to Unveil Third Quarter Performance Alright, folks, we're spinning the wheel again and betting on Sun Life Financial's (TSX: SLF) third quarter earnings, taking the spotlight on November 4, 2026. Anyone eyeballing this should circle their calendars, tie their shoelaces, and get prepared. Since they're laying out the details after the markets shut, looks...

Continue Reading
Middle East's Premier Jewellery Event: A Game-Changer

Updated Category News Views 4

An Event Gemmed with Strategic Importance The Middle East is about to see its streets glitter even more than usual. Next week, the Jewellery, Gem & Technology in Dubai (JGTD) event rolls into town, packed with brands that’ll drop in like swanky diamonds. We’re talking 300 heavy-duty exhibitors from all corners of the globe, ready to strut their stuff at the DEC Expo...

Continue Reading
Groundbreaking Sale: Lani Automotive Acquires Iowa Dealership

Updated Category News Views 9

A shift in the automotive retail world takes place with Lani Automotive Group's latest move. They've just picked up their first franchised dealership, Mount Pleasant Chevrolet GMC Chrysler Dodge Jeep Ram in Iowa. It's a mouthful, sure, but it packs a punch in terms of potential growth. Why This Sale Stands Out The deal was brokered by Performance Brokerage Services, which...

Continue Reading
Reverie Saigon Triumphs: Triple Acclaims in Global Awards

Updated Category News Views 5

A Celebration Beyond the Ordinary Now, if there's one thing the travel folks adore; it’s a hotel that isn’t just selling beds but an experience—a place where luxury meets soul. The Reverie Saigon in Ho Chi Minh City has snagged not one, but three prestigious accolades, and that’s worth more than just a passing glance. Exceptional Honors Across the Globe You...

Continue Reading
AceMyNursingExams Debuts Versatile Nursing Prep Platform

Updated Category News Views 5

A Digital Lifeline for Nursing Students Nursing students are buried in responsibilities: lectures, clinical rotations, and sometimes even a job to fund the whole marathon. And just when they think they’ve got it handled, boom, a mountain of exams rises up in front of them. AceMyNursingExams gets this, rolling out an online exam prep platform to keep these future...

Continue Reading
World Treadmill Championship: A New Run Begins

Updated Category News Views 7

A Run Like No Other I’ll bet you’ve heard it all when it comes to races—winding city marathons, grueling ultras with rough terrain, and everything in between. But a world championship on treadmills? Now that's a fresh spin! October 23rd, 2026 is when the RUN X™ World Treadmill Championship kicks off, stretching out across the planet in 400 fitness centres...

Continue Reading
Ziihera Extends Survival in Advanced GEA: Big Gains Ahead?

Updated Category News Views 3

A Hard Look at Ziihera's Three-Year Survival Story You know the drill—anytime a new drug pulls weight in the cancer arena, ears perk up. Jazz Pharmaceuticals' recent unveil at the 2026 ESMO Congress caught my attention like a solid run on the NASDAQ. We're looking at Ziihera, tangoing with tislelizumab and chemotherapy, hauling serious results against the nasty fight of...

Continue Reading

Top 5 Most Recently Viewed Articles

Keynote Speakers Announced for 2026 ISPE Aseptic Conference

Updated Category News Views 133

2026 ISPE Aseptic Conference Overview The upcoming 2026 ISPE Aseptic Conference is scheduled to take place in March and will welcome participants both in person and virtually. This important event will gather industry professionals, innovators, and regulators in a forum aimed at advancing the science and application of aseptic processing and sterile manufacturing. Keynote...

Continue Reading
Celebrating Cinema at the 20th China Film Huabiao Awards

Updated Category News Views 602

A Glimpse into the 20th China Film Huabiao Awards The eagerly anticipated 20th China Film Huabiao Awards is around the corner, taking place in a vibrant and artistic atmosphere. This ceremony not only celebrates individual achievements in the film industry but also marks a significant milestone for Chinese cinema, which has seen remarkable growth over the last century....

Continue Reading
Significant Growth in Optimism Coin Pricing and Activity

Updated Category News Views 90

Optimism (OP) Price Jumps Optimism, the OP token, has stepped into the spotlight with a sharp daily move: up 6.48% in the last 24 hours to $1.60. That daily rise builds on a strong week, where OP climbed more than 17.0%, moving from $1.36 to its current level. Placed against its all-time high of $4.84, today’s price sits well below the peak, a reminder of how far the...

Continue Reading
What Investors Should Know About Annaly Capital Management Now

Updated Category News Views 169

Annaly Capital Management's Upcoming Earnings Report Annaly Capital Management (NYSE:NLY) is scheduled to release its quarterly earnings report soon. Investors are eager to find out how the company is performing and what it might mean for future investments. Analysts predict an earnings per share (EPS) of $0.72, and there is hope that the company will not only meet but...

Continue Reading
UBS Group's Remarkable Performance and Growth Over 5 Years

Updated Category News Views 264

UBS Group: A Powerhouse on the Financial Scene In an era where stock performances often leave investors scratching their heads, UBS Group (NYSE: UBS) has carved out a prominent niche with its stellar market growth. Over the past five years, this banking giant has not just weathered economic storms; it’s thrived, boasting an annual growth rate that surpasses the general...

Continue Reading